Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuronal correlates of dysfunctional attention components in schizophrenia treated with galantamine
2005-003245-14Phase 4Completed
- Sponsor
- Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen
- Start
- Sep 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of galantamine in schizophrenia, sponsored by Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen. Primary endpoint: Change in cognitive/attentional function and neuronal correlates at 6 weeks. Started Sep 2006; status: completed.
02
Drugs
galantamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-003245-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003245-14.